Previous 10 | Next 10 |
An open-label Phase 2 clinical trial evaluating Albireo Pharma's ( ALBO -3.9% ) lead candidate A4250 in pediatric Alagille syndrome and biliary atresia patients for the treatment of cholestasis (restricted or blocked bile flow) showed a positive effect . The results were presented at The ...
- Reduction in serum bile acids and pruritus observed in both populations – - Alagille abstract selected for inclusion in ’Best of ILC’ – - Albireo plans to initiate second A4250 pivotal program in biliary atresia second half of 2019 – ...
The FDA has cleared Albireo Pharma's (NASDAQ: ALBO ) IND application for a Phase 2 clinical trial of elobixibat, once-daily, orally-available ileal bile acid transporter (IBAT) inhibitor, for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)....
– Initiation of Phase 2 clinical trial expected in Q2 2019 – – IBAT inhibition has potential to impact key markers of NASH – BOSTON, April 11, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver dise...
BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April: H.C. Wainwrigh...
BOSTON, March 27, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that results from its completed Phase 2 clinical trial of lead product candidate A4250 in children w...
-- Significant recent rare disease product launch and access experience -- -- Key addition as Albireo prepares for commercialization of A4250 -- BOSTON, March 21, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company dev...
Albireo Pharma, Inc. (ALBO) Q4 2018 Earnings Conference Call March 7, 2019 08:30 ET Company Participants Paul Arndt - Investor Relations Ron Cooper - President and Chief Executive Officer Patrick Horn - Chief Medical Officer Simon Harford - Chief Financial Officer Conference...
Albireo Pharma (NASDAQ: ALBO ): FY GAAP EPS of -$3.94. More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- A4250 Phase 3 PFIC pivotal program on target for end of ‘19/early ’20 topline readout - - Plan to initiate second A4250 pivotal program in biliary atresia - - Plan to initiate Phase 2 study with elobixibat in NASH - - Management to host conference call and webcast tod...
News, Short Squeeze, Breakout and More Instantly...
Albireo Pharma Inc. Company Name:
ALBO Stock Symbol:
NASDAQ Market:
Bylvay (odevixibat) granted Priority Review by U.S. FDA ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients Approval in second indication would more than double Bylvay market oppo...
Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca , while Albireo Pharma (NASDAQ: ALBO) is set to be owned by ...
The Nasdaq Composite (NASDAQINDEX: ^IXIC) might finally be looking to gain some momentum in 2023, with investors desperately wanting a reversal from 2022's horrible performance. Sizable gains on Friday helped to build more positive sentiment, and the bullish move continued on Monday morni...